Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: Results from the Swedish biologics register

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1186-1193

  Forsblad d'Elia, Helena ^a   Bengtsson, Karin ^a   Kristensen, Lars Erik ^b   Jacobsson, Lennart T H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical response; Drug survival; Outcome; Predictor; Register; Tocilizumab

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB;

ADOLESCENT; ADULT; ARTICLE; CORTICOSTEROID THERAPY; DAS28; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPEAN LEAGUE AGAINST RHEUMATISM; EVALUATION STUDY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; SURVIVAL; SWEDEN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 84936865551     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu455     Document Type: Article

References (30)

1. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
2. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371:987-97.
3. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58: 2968-80.
4. Yazici Y, Curtis JR, Ince A et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to diseasemodifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71:198-205.
5. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
6. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
7. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
8. Yamanaka H, Tanaka Y, Inoue E et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011; 21:122-33.
9. Nakashima Y, Kondo M, Harada H et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20:343-52.
10. Leffers HC, Ostergaard M, Glintborg B et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70:1216-22.
11. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013;32:1347-55.
12. Pers YM, Fortunet C, Constant E et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 2014;53:76-84.
13. Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012;71:382-5.
14. Kievit W, Fransen J, Adang EM et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50: 196-203.
15. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62:22-32.
16. Yazici Y, Krasnokutsky S, Barnes JP et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36: 907-13.
17. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
18. Askling J, Fored CM, Geborek P et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
19. Neovius M, Simard J, Sundstrom A et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011;70:516-9.
20. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
22. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
23. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a fiveyear observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
24. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381: 1541-50.
25. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;75:1897-904.
26. Kojima T, Yabe Y, Kaneko A et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 2013;23:977-85.
27. Bykerk VP, Ostor AJ, Alvaro-Gracia J et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 2012;71:1950-4.
28. Burmester GR, Feist E, Kellner H et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9.
29. Kristensen LE, Kapetanovic MC, Gulfe A et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:495-9.
30. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.